Screening practices for late effects in pediatric patients on tyrosine kinase inhibitors.

被引：0
|
作者：
Smith, Stephanie M.
Sabnis, Himalee S.
Lewis, Rebecca Williamson
Effinger, Karen Elizabeth
Bergsagel, Daniel John
Patterson, Briana
Mertens, Ann C.
Sakamoto, Kathleen
Schapira, Lidia
Castellino, Sharon M.
机构：
[1] Stanford Univ, Dept Pediat, Sch Med, Div Hematol Oncol, Stanford, CA 94305 USA
[2] Childrens Healthcare Atlanta, Dept Pediat, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA
[3] Emory Univ, Atlanta, GA 30322 USA
[4] Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA USA
[5] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA
[6] AFLAC Canc Ctr & Blood Disorders Svc, Atlanta, GA USA
[7] Emory Univ, Sch Med, Dept Pediat, Div Endocrinol, Atlanta, GA USA
[8] Stanford Univ, Stanford, CA 94305 USA
[9] Stanford Canc Inst, Stanford, CA USA
[10] Childrens Healthcare Atlanta, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e22527
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Late Responses in Patients With Chronic Myeloid Leukemia Initially Refractory to Tyrosine Kinase Inhibitors
    Shaya, Justin
    Pettit, Kristen
    Kandarpa, Malathi
    Bixby, Dale
    Mercer, Jessica
    Talpaz, Moshe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (01): : 17 - 23
  • [42] Cardiovascular adverse effects of Bruton tyrosine kinase inhibitors: Pathophysiological mechanisms, screening, and management
    Cautela, Jennifer
    Croizier, Carolyne
    Inchiappa, Luca
    Goncalves, Trecy
    Stocker, Nicolas
    Tchernonog, Emmanuelle
    BULLETIN DU CANCER, 2024, 111 (12) : 1142 - 1153
  • [43] Analysis of bleeding risk with concurrent treatment of VEGFR tyrosine kinase inhibitors (TKIs) and factor Xa inhibitors.
    George, Tiffany L.
    Patel, Sandip H.
    Wang, Tzu-Fei
    Mori-Vogt, Sherry
    Folefac, Edmund
    Yin, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Adverse Effects of Combined Tyrosine Kinase Inhibitors
    Lu, Shun
    Li, Ziming
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (11) : E182 - E183
  • [45] EFFECTS OF RECEPTOR TYROSINE KINASE INHIBITORS ON MENINGIOMAS
    Li, Li
    Daou, Marie-Claire
    Mihaliak, Alicia
    Moser, Richard
    Smith, Thomas
    Ross, Alonzo H.
    NEURO-ONCOLOGY, 2009, 11 (05) : 638 - 638
  • [46] Management of side effects of tyrosine kinase inhibitors
    Woelfler, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 229 - 229
  • [47] Laryngeal Side Effects of Tyrosine Kinase Inhibitors
    Tamir, Sharon Ovnat
    Milk, Dafna Gershnabel
    Roth, Yehudah
    Cinamon, Udi
    Winder, Asher
    Brenner, Ronen
    Katz, Ariel
    Marom, Tal
    JOURNAL OF VOICE, 2016, 30 (05) : 606 - 610
  • [48] Characterization of mouse hepatocellular carcinoma cell lines to understand resistance to tyrosine kinase inhibitors.
    Zhou, Shuang
    Abe, Yuichi
    Kajino, Taisuke
    Isomura, Hisanori
    Yamaguchi, Rui
    Ishigami, Masatoshi
    Fujishiro, Mitsuhiro
    Taguchi, Ayumu
    CANCER SCIENCE, 2024, 115 : 1909 - 1909
  • [49] Binding mode of VEGF receptor tyrosine kinase KDR (VEGFR-2) inhibitors.
    McGaughey, G
    Bilodeau, M
    Coll, K
    Gibbs, J
    Hartman, G
    Huckle, W
    Hungate, R
    Johnson, A
    Kendall, R
    Koester, T
    Kohl, N
    Mao, XZ
    McFall, R
    Pan, BS
    Rickert, K
    Rodman, L
    Rutledge, R
    Thomas, K
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U482 - U482
  • [50] Synthesis and evaluation of 6-acrylamido4-phenylaminoquinazolines as tyrosine kinase EGFR inhibitors.
    Nandanan, E
    VanBrocklin, HF
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U186 - U186
12345